Medicenna Therapeutics Corp 6-K, filed Oct 24, 2023
Medicenna Therapeutics Corp. (MDNAF)
About this 6-K
Medicenna Therapeutics Corp filed this 6-K on October 24, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2023
Commission File Number: 001-39458
Medicenna Therapeutics Corp.
(Translation of registrant's name into English)
2 Bloor St. W., 7th Floor
Toronto, Ontario M4W 3E2, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
EXHIBIT INDEX
| Exhibit Number | Description | |
| 99.1 | Press Release dated October 24, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Medicenna Therapeutics Corp. | ||
| Date: October 24, 2023 | By: | /s/ Fahar Merchant, PhD |
| Name: Fahar Merchant, PhD | ||
| Title: Chief Executive Officer | ||
EXHIBIT 99.1
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) to be held in San Diego, CA, from November 1-5th, 2023.
The company will present an update from its Phase 1/2 ABILITY Study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, a long-acting, beta-enhanced IL-2 Superkine. In addition, pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 superkine, will also be presented at the conference.
Poster presentation details:
- Title: Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a Phase 1/2 trial with MDNA11 in patients with advanced solid tumors
- Poster Number: 760
- Presentation Date: Saturday, November 4, 2023, 9:00 am to 8:30 pm PDT
- Title: Characterization of a tumor-targeting and activatable T-MASK platform to enhance tumor accumulation and tolerability of potent immune modulators
- Poster Number: 1071
- Presentation Date: Friday, November 3, 2023, 9:00 am to 7:00 pm PDT
About Medicenna
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class class-empowered superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™ program (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
Further Information & Investor Contact:
Delphine Davan
Vice President, Investor Relations and Corporate Communications,
Phone: +1 (647) 474-2641
ddavan@medicenna.com